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patients randomized to SIR/TAC received one year of SIR
following HCT, while MTX/TAC patients received MTX on
days 1, 3, 6, and 11. QOL was assessed with the Functional
Assessment of Cancer Therapy e Bone Marrow Transplant
Treatment Outcome Index (TOI) prior to HCT and day 30, 90,
180, 270, and 360 following HCT. Random effects models
were used to examine longitudinal trajectories of QOL
between day 30 and 360 by study arm, controlling for
baseline TOI scores.
Results: A total of 74 patients were enrolled (37 per study
arm); all contributed data to these analyses. Analyses indi-
cated that the MTX/TAC group showed greater improvement
in TOI scores over time compared to the SIR/TAC group
(P ¼ .02); by day 360, the average difference between groups
was 7.18 points (P ¼ .03). This effect continued to be signiﬁ-
cant (P < .01) when controlling for clinical differences
between groups, including acute GVHD, chronic GVHD, and
anemia. Exploratory analyses of subscales comprising the
TOI [i.e., Physical Well-Being (PWB), Functional Well-Being
(FWB), BMT Scale (BMTS)] indicated that group differences
were due to greater improvement in PWB in the MTX/TAC
group (P ¼ .02). Additional exploratory analyses of items on
the PWB scale indicated that members of the SIR/TAC arm
were more likely to endorse a lack of energy and nausea over
time (ps.01). Study arm differences on these items per-
sisted when controlling for acute GVHD, chronic GVHD, and
anemia (ps<.01).
Conclusions: Data from the current study indicate that SIR/
TAC is associated with less improvement in QOL in the ﬁrst
year post-HCT compared to MTX/TAC. This difference is not
attributable to other potential clinical differences between
study arms, including acute and chronic GHVD and anemia.
Differences in QOL appear to result in part from greater
fatigue and nausea in participants treated with SIR, which
was administered throughout the one year follow-up period.77
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Background: Characterisation of late effects in children
undergoing hematopoietic stem cell transplant (HSCT) for
non-malignant diseases is challenging due to the small
numbers of rare diseases, variations in cancer susceptibility
and organ toxicity associated with primary diagnosis as well
as non-uniform clinical practice. In addition, limited follow-
up in previous studies may have underestimated the risk of
second cancers and late deaths in this group of transplant
recipients. Our study used population-based registry data to
determine the risk of malignancy and late mortality inpediatric patients transplanted for non-malignant
conditions.
Methods: 318 Australian allogeneic transplant recipients
aged less than 15 years, treated from 1982-2007 for non-
malignant conditions, were identiﬁed from children's
hospitals and the Australasian Bone Marrow Transplant
Recipient Registry (ABMTRR). Clinical and demographic data
were obtained from the ABMTRR and medical records.
Linkage with the Australian Cancer Database and National
Death Index was performed to identify all primary invasive
cancers and deaths in this cohort. Standardised incidence
ratios (SIRs) were generated for second malignancies and
deaths in 2-year survivors.
Results: Indications for HSCT included; primary immuno-
deﬁciencies (n¼130), aplastic anemia (SAA, n¼71), inherited
marrow failure syndromes (n¼51), thalassemia (n¼14) and
hemophagocytic lymphohistiocytosis (n¼14). Over two
thirds of recipients weremale (69%), while the median age at
transplant was 3 years (range 0-14y) A total of 43 patients
received radiation therapy as part of their conditioning
regimen.
Six malignancies were identiﬁed in male patients with
various diseases including Fanconi Anemia (2), Severe
Aplastic Anemia (1), severe combined immune deﬁciency
(1), Thalassemia (1) and chronic granulomatous disease
(n¼1). The most common second cancer was squamous cell
carcinoma of the tongue. Overall there was a 15-fold
increased risk of malignancy compared to the Australian
general population (SIR¼15.37, 95%CI¼6.91-34.21).
Two thirds of patients (62%) survived for more than 2
years after HSCT, while the cumulative incidence of late
death was 2.1% at 5 years from HSCT and 6.3% at 10 years
from HSCT. Overall, the rate of death was 17 times greater
than expected compared to the general population, with
cancer being the most common cause of death.
Conclusion: These ﬁndings show an increased rate of
malignancy and late death in Australian pediatric patients
transplanted for non-malignant conditions compared to the
general population. This conﬁrms the need for long term
surveillance to maximize the early detection of subsequent
malignancies, which may occur a decade or more after
HSCT.78
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Background: Increasing indications for transplant and
improvements in early transplant outcomes have lead to an
